LWK Stock Overview
A biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
eFFECTOR Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.08 |
| 52 Week High | US$15.88 |
| 52 Week Low | US$1.06 |
| Beta | 0.62 |
| 1 Month Change | 0% |
| 3 Month Change | 0.47% |
| 1 Year Change | -90.89% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| LWK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.6% | 0.8% |
| 1Y | -90.9% | -13.5% | 15.0% |
Return vs Industry: LWK underperformed the German Biotechs industry which returned -17% over the past year.
Return vs Market: LWK underperformed the German Market which returned 6.8% over the past year.
Price Volatility
| LWK volatility | |
|---|---|
| LWK Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: LWK has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LWK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 14 | Craig Jalbert | effector.com |
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company’s lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer.
eFFECTOR Therapeutics, Inc. Fundamentals Summary
| LWK fundamental statistics | |
|---|---|
| Market cap | €182.26k |
| Earnings (TTM) | -€31.02m |
| Revenue (TTM) | n/a |
Is LWK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LWK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$21.62m |
| Gross Profit | -US$21.62m |
| Other Expenses | US$13.02m |
| Earnings | -US$34.63m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2,420.3% |
How did LWK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/21 07:12 |
| End of Day Share Price | 2024/06/24 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
eFFECTOR Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Judah Frommer | Credit Suisse |
| Robert Burns | H.C. Wainwright & Co. |